 |
|
|
| |
Doravirine (DOR) Versus Ritonavir-Boosted Darunavir (DRV+r): 96-Week Results of the Randomized, Double-Blind, Phase 3 DRIVE-FORWARD Noninferiority Trial
|
| |
| |
Reported by Jules Levin
22nd International AIDS Conference; July 23-27, 2018; Amsterdam, the Netherlands
Jean-Michel Molina,1 Kathleen Squires,2* Paul E. Sax,3 Pedro Cahn,4 Johan Lombaard,5 Edwin DeJesus,6 Ming-Tain Lai,2 Xia Xu,2 Anthony Rodgers,2 Lisa Lupinacci,2 Sushma Kumar,2 Peter Sklar,2 Bach-Yen T. Nguyen,2 George J. Hanna,2 Carey Hwang2 and Elizabeth Martin2 for the DRIVE-FORWARD trial Group
1University of Paris 7, Hopital St Louis, Paris, France; 2Merck & Co., Inc., Kenilworth, NJ, USA; 3Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; 4Fundacion Huesped, Buenos Aires, Argentina; 5Josha Research, Bloemfontein, South Africa; 6Orlando Immunology Center, Orlando, FL, USA
*At Sidney Kimmel Medical College of Thomas Jefferson University at the time this research was conducted.
|
| |
|
|
|
|
|
